A single-centre approach for a safe and individualized tolerization phase for the treatment of PUPs with severe haemophilia A

Introduction Pediatricians treating newly diagnosed severe haemophilia A patients are confronted with the challenge to protect the children against bleeds that are potentially life-threatening or may have long-term damaging effects on joints. The protection that early prophylaxis with coagulation factor VIII (FVIII) provides, may however put the patients at risk for inhibitor development. We report our experience with an individualized approach to managing PUPs at a single haemophilia treatment center (HTC) in Germany.